World Antiviral Congress

THURSDAY 12 NOVEMBER 2020

VIRTUAL LIVE EVENT

 
 

BriNging translational antiviral drug discovery and development to the market

 

 
 


THE NEED FOR THE NEW ANTIVIRAL AGENT

 

Evident with every viral pandemic including COVID-19, rapid deployment of compatible antiviral therapies is of paramount importance, particularly before a long-term strategy of a vaccine is possible.

Antivirals can prevent or control viral diseases from emerging diseases, respiratory infections, chronic diseases to virus-associated tumours.

Join us on this virtual congress to get up to speed and help accelerate your antiviral research from bench to patient.


Brought to you by the World Vaccines Congress Series team

world vaccine congress Washington

EVENT UPDATES

For event updates, discounts and latest news sign up now.

Sign Up for Event Updates

TOP SPEAKERS FROM OUR VACCINE SERIES

Some of the most exciting industry speakers participate in the series including:

 

Dr Tedros Adhanom Ghebreyesus, Director General, WHODr Tedros Adhanom Ghebreyesus
Director General
WHO

Dr Anthony S. Fauci, M.D. NIAID Director NIHDr Anthony S. Fauci, M.D.
NIAID Director
NIH

Dr Marco Cavaleri, Head of Office, Anti-infective and Vaccines in the Human, Medicines Evaluation Division, EMA Dr Marco Cavaleri;
Head of Office, Anti-infective and Vaccines in the Human, Medicines Evaluation Division  
EMA

Dr Kate O’Brien Director, Department of Immunization, Vaccines and Biologicals WHO Dr Kate O’Brien;
Director, Department of Immunization, Vaccines and Biologicals;
WHO

Dr Sarah Gilbert, Prof of Vaccinology, Jenner Institute, University of Oxford Dr Sarah Gilbert 
Prof of Vaccinology
Jenner Institute, University of Oxford

Dr Mariola Fotin-Mleczek, CSO, Curevac Dr Mariola Fotin-Mleczek
CSO 
Curevac

Professor Jean-Jacques Muyembe-Tamfum, Director-General, National Institute for Biomedical Research, Democratic Republic of the Congo (DRC) & Professor of Microbiology; Kinshasa University Medical School Prof. Jean-Jacques Muyembe-Tamfum  
Director-General, National Institute for Biomedical Research, Democratic Republic of the Congo (DRC) & Professor of Microbiology
Kinshasa University Medical School

Dr Richard Hatchett, CEO, CEPI Dr Richard Hatchett
CEO
CEPI

Dr Klaus Cichutek, President, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Germany & Professor of Biochemistry, Goethe University Frankfurt/Main Dr Klaus Cichutek
Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Germany & Professor of Biochemistry 
Goethe University Frankfurt/Main

Dr Marion Gruber  , Director, OVRR, CBER, FDA Marion Gruber
Director, OVRR, CBER
FDA

Dr Paul Stoffels Vice Chairman of the Executive Committee and Chief Scientific Officer Janssen Dr Paul Stoffels 
Vice Chairman of the Executive Committee and Chief Scientific Officer
Janssen

John Markels, President, Merck Vaccines Dr John Markels  
President
Merck Vacines

ANTIVIRAL CONGRESS FEATURES:

 

World Antiviral Congress

Exclusive
Interviews

World Antiviral Congress

World Leading
Presentations

World Antiviral Congress

Interactive
Roundtables

World Antiviral Congress

Live Panel
Debates

World Antiviral Congress

Virtual Face-to-Face Meetings

World Antiviral Congress

Webinars
All Year Round

 


"The third breakthrough will be in antiviral drugs. These have been an underinvested branch of science. We haven’t been as effective at developing drugs to fight viruses as we have those to fight bacteria. But that will change. Researchers will develop large, diverse libraries of antivirals, which they’ll be able to scan through and quickly find effective treatments for novel viruses."

Bill Gates, writing in The Economist, April 23 2020
 


Join thousands of antiviral drug development & discovery leaders this November


Grab FREE tickets by end of July!

 
 

 

 

 

Get involved in World Antiviral Congress

 

  For sponsorship opportunities

thomas.hall@terrapinn.com

For speaking opportunities

elena.dimitriou@terrapinn.com